Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study
Launched by MAYO CLINIC · Aug 3, 2021
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
1. To extend recruitment at all 8 LEO centers as part of LEO2.0 using a single IRB, with a goal of recruiting an additional 8,000 newly diagnosed NHL patients (with funding from the NIH renewal grant to enroll 3,400) focused on Hispanic (N=900), African Americans (N=580), and Asian (N=200) participants (doubling the current sample size for these groups; adolescent and young adult patients age 18-39 years (N=870; 87% increase); and non-metro and rural patients of all ages and race/ethnicities (N=1,208, 72% increase) for a total cohort of over 21,000 patients;
2. To review pathology at diagno...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Newly diagnosed non-Hodgkin Lymphoma (NHL), within 183 days of enrollment
- • Patients may have been treated as long as initial NHL diagnosis is within 6 months of enrollment
- • 18 years of age or older
- Exclusion Criteria:
- • - Lymphoma diagnosis greater than 184 days from date of consent
About Mayo Clinic
Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Iowa City, Iowa, United States
Rochester, New York, United States
Atlanta, Georgia, United States
Scottsdale, Arizona, United States
Jacksonville, Florida, United States
Houston, Texas, United States
Rochester, Minnesota, United States
New York, New York, United States
Saint Louis, Missouri, United States
Miami, Florida, United States
Saint Louis, Missouri, United States
Patients applied
Trial Officials
James R Cerhan, MD,PhD
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials